UNIGE document Scientific Article
previous document  unige:110671  next document
add to browser collection
Title

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease

Authors
Fautrel, Bruno
Rech, Jürgen
Spertini, François
Feist, Eugen
Kötter, Ina
Hachulla, Eric
Morel, Jacques
show hidden authors show all authors [1 - 17]
Published in Annals of the Rheumatic Diseases. 2018, vol. 77, no. 6, p. 840-847
Abstract Adult-onset Still's disease (AOSD) is a rare systemic autoinflammatory disease; its management is largely empirical. This is the first clinical study to determine if interleukin (IL)-18 inhibition, using the recombinant human IL-18 binding protein, tadekinig alfa, is a therapeutic option in AOSD.
Identifiers
PMID: 29472362
Full text
Article (Published version) (727 Kb) - public document Free access
Structures
Research group Mécanisme de l'inflammation articulaire (44)
Citation
(ISO format)
GABAY, Cem et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. In: Annals of the Rheumatic Diseases, 2018, vol. 77, n° 6, p. 840-847. doi: 10.1136/annrheumdis-2017-212608 https://archive-ouverte.unige.ch/unige:110671

191 hits

106 downloads

Update

Deposited on : 2018-11-12

Export document
Format :
Citation style :